Active ingredientValemetostatCat. No. P-V007-001CAS 1809336-39-7Family · Pharmaceutical analytical standards
Valemetostat
A dual inhibitor of the enzymes EZH1 and EZH2, involved in the origin of some non-Hodgkin lymphomas; it was approved in Japan in 2022 for relapsed or refractory adult T-cell leukaemia/lymphoma. This family brings together the active ingredient and labelled standards.
Did you know?The disease it was approved for is caused by the HTLV-1 virus, the first human retrovirus ever identified, and it had been first described in Japan itself, in 1977.
Go to the active ingredient →Active ingredientValemetostatCat. No. P-V007-001CAS 1809336-39-7
Isotopically labelledValemetostat-d6Cat. No. P-V007-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.